Cargando…

Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment

[Image: see text] Liver cirrhosis is a chronic disease that affects the liver structure, protein expression, and overall metabolic function. Abundance data for drug-metabolizing enzymes and transporters (DMET) across all stages of disease severity are scarce. Levels of these proteins are crucial for...

Descripción completa

Detalles Bibliográficos
Autores principales:	El-Khateeb, Eman, Achour, Brahim, Al-Majdoub, Zubida M., Barber, Jill, Rostami-Hodjegan, Amin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424631/ https://www.ncbi.nlm.nih.gov/pubmed/34428046 http://dx.doi.org/10.1021/acs.molpharmaceut.1c00462

Ejemplares similares

Quantitative Proteomics of Hepatic Drug‐Metabolizing Enzymes and Transporters in Patients With Colorectal Cancer Metastasis
por: Vasilogianni, Areti‐Maria, et al.
Publicado: (2022)

Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine
por: Couto, Narciso, et al.
Publicado: (2020)

Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects
por: Vasilogianni, Areti‐Maria, et al.
Publicado: (2021)

Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters
por: Achour, Brahim, et al.
Publicado: (2020)

Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
por: Vasilogianni, Areti-Maria, et al.
Publicado: (2023)

Mass spectrometry‐based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin
por: Al‐Majdoub, Zubida M., et al.
Publicado: (2020)

Quantification of Proteins Involved in Intestinal Epithelial Handling of Xenobiotics
por: Al‐Majdoub, Zubida M., et al.
Publicado: (2020)

In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition
por: Murata, Yukiko, et al.
Publicado: (2022)

Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P‐Glycoprotein Activities
por: Achour, Brahim, et al.
Publicado: (2022)

Editorial: Precision Medicine: Impact of Cytochromes P450 and Transporters Genetic Polymorphisms, Drug-Drug Interactions, Disease on Safety and Efficacy of Drugs
por: Daali, Youssef, et al.
Publicado: (2022)

Altered Bioavailability and Pharmacokinetics in Crohn’s Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs
por: Alrubia, Sarah, et al.
Publicado: (2022)

Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically‐Based Pharmacokinetic Modeling and Dose Adjustment
por: Tan, Shawn Pei Feng, et al.
Publicado: (2022)

Precision dosing to avoid adverse drug reactions
por: Polasek, Thomas M., et al.
Publicado: (2019)

Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling
por: Doki, Kosuke, et al.
Publicado: (2019)

A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine
por: Jamei, M., et al.
Publicado: (2013)

The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study
por: Cristea, Sînziana, et al.
Publicado: (2020)

Synthesis of uniform cyclodextrin thioethers to transport hydrophobic drugs
por: Becker, Lisa F, et al.
Publicado: (2014)

Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments
por: Calvier, Elisa A. M., et al.
Publicado: (2018)

Inhibition of aggregation of amyloid-β through covalent modification with benzylpenicillin; potential relevance to Alzheimer's disease
por: Alsalahat, Izzeddin, et al.
Publicado: (2021)

Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease
por: El-Khateeb, Eman, et al.
Publicado: (2023)

Animal versus human oral drug bioavailability: Do they correlate?
por: Musther, Helen, et al.
Publicado: (2014)

Application of the Nested Enzyme‐Within‐Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic Effects
por: Takita, Hiroyuki, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making
por: Rowland, M, et al.
Publicado: (2015)

Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence
por: Rostami‐Hodjegan, Amin
Publicado: (2017)

The Need for Uniformity in the Quality of Drugs
Publicado: (1908)

Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability
por: Chetty, Manoranjenni, et al.
Publicado: (2014)

Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine‐Drug Interactions
por: Scotcher, Daniel, et al.
Publicado: (2020)

Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
por: Frechen, Sebastian, et al.
Publicado: (2022)

Mechanisms of promiscuity among drug metabolizing enzymes and drug transporters
por: Atkins, William M.
Publicado: (2019)

Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia
por: Getachew, Henok, et al.
Publicado: (2015)

Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective
por: Briki, Myriam, et al.
Publicado: (2023)

Predicted Vancomycin Dosage Requirement in Patients With Hematological Malignancies and Dosage Dynamic Adjustment
por: Song, Xiangqing, et al.
Publicado: (2022)

Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate
por: Rostami‐Hodjegan, Amin, et al.
Publicado: (2021)

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model
por: Almond, Lisa M., et al.
Publicado: (2016)

Personalized Drug Dosage – Closing the Loop
por: Tucker, Geoffrey T
Publicado: (2016)

The Rate of Antibiotic Dosage Adjustment in Renal Dysfunction
por: Fahimi, Fanak, et al.
Publicado: (2012)

Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters
por: Ahmad, Amais, et al.
Publicado: (2021)

Single‐cell isogrowth profiling: Uniform inhibition uncovers non‐uniform drug responses
por: Lukačišin, Martin, et al.
Publicado: (2022)

Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method
por: Calvier, E. A. M., et al.
Publicado: (2019)

Awareness and current implementation of drug dosage adjustment by pharmacists in patients with chronic kidney disease in Japan: a web-based survey
por: Kondo, Yuki, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s38dvc44ubiekp7p5huqckj5q3